These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18234554)

  • 1. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Stroud RE; McKelvie RS; Liu PP
    Eur J Heart Fail; 2008 Feb; 10(2):125-8. PubMed ID: 18234554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
    Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
    J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
    Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
    J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
    J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy.
    Neuhold S; Huelsmann M; Strunk G; Struck J; Adlbrecht C; Gouya G; Elhenicky M; Pacher R
    Clin Chem; 2010 Jan; 56(1):121-6. PubMed ID: 19884490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
    JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart.
    Vianello A; Caponi L; Franzoni F; Galetta F; Rossi M; Taddei M; Malvaldi G; Pietrini P; Santoro G
    Clin Sci (Lond); 2009 Jul; 117(4):157-64. PubMed ID: 19196241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia.
    Finkelstein A; Michowitz Y; Abashidze A; Miller H; Keren G; George J
    Atherosclerosis; 2005 Apr; 179(2):353-9. PubMed ID: 15777553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.
    Täger T; Wiebalck C; Fröhlich H; Corletto A; Katus HA; Frankenstein L
    Clin Res Cardiol; 2017 Dec; 106(12):974-985. PubMed ID: 28779229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations.
    Groenning BA; Nilsson JC; Sondergaard L; Kjaer A; Larsson HB; Hildebrandt PR
    Eur J Heart Fail; 2001 Dec; 3(6):699-708. PubMed ID: 11738222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neurohormonal activation in congestive heart failure: does it normalize after heart transplantation?].
    Pérez-Villa F; Roig E; Ferrer E; Cuppoletti A; Llancaqueo M; Jiménez W; Sanz G
    Rev Esp Cardiol; 2004 Aug; 57(8):725-31. PubMed ID: 15282060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure.
    Klinge R; Hystad M; Kjekshus J; Karlberg BE; Djøseland O; Aakvaag A; Hall C
    Scand J Clin Lab Invest; 1998 Dec; 58(8):683-91. PubMed ID: 10088206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction.
    Squire IB; Evans J; Ng LL; Loftus IM; Thompson MM
    J Card Fail; 2004 Aug; 10(4):328-33. PubMed ID: 15309700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.
    Sigurdsson A; Eriksson SV; Hall C; Kahan T; Swedberg K
    Eur J Heart Fail; 2001 Jan; 3(1):69-78. PubMed ID: 11163738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.